Clinical Report: Interim Phase 2 Data on Laru-zova Gene Therapy for XLRP
Overview
Beacon Therapeutics presented 6-month interim results from the DAWN phase 2 trial of laru-zova, a gene therapy for X-linked retinitis pigmentosa (XLRP), showing promising improvements in visual function and a favorable safety profile. The therapy targets restoration of both rod and cone photoreceptor function by delivering a functional RPGRORF15 gene.
Background
X-linked retinitis pigmentosa (XLRP) is a genetic retinal disorder characterized by progressive vision loss due to mutations in the RPGR gene affecting photoreceptors. Current treatments are limited, and gene therapy offers a potential approach to restore retinal function. Laru-zova (laruparetigene zovaparvovec) is designed to deliver a codon-optimized full-length RPGRORF15 gene using a proprietary vector optimized for photoreceptor transduction. The DAWN trial evaluates safety and efficacy of laru-zova in patients previously treated with AAV vector-based RPGR gene therapy, focusing on the untreated eye.
Data Highlights
| Parameter | Outcome at 6 Months |
|---|---|
| Safety | Generally well-tolerated with no new safety signals |
| Visual Function | Promising improvements across several key measures |
| Dose Levels | Two dose levels assessed for efficacy and tolerability |
| Patient Population | Participants previously treated with full-length AAV RPGR gene therapy |
Key Findings
- Laru-zova gene therapy was generally well-tolerated in all participants evaluated at 6 months or beyond.
- Promising improvements in visual function were observed across multiple key measures.
- The therapy delivers a codon-optimized full-length RPGRORF15 gene using a proprietary capsid vector optimized for photoreceptor transduction.
- DAWN is an open-label study assessing two dose levels in the untreated eye of patients previously treated with RPGR gene therapy.
- Enrollment continues for the pivotal phase 2/3 VISTA trial to further evaluate laru-zova in XLRP patients.
Clinical Implications
The interim data suggest that laru-zova may offer a safe and effective gene therapy option for patients with XLRP, including those previously treated with gene therapy. These findings support continued development and enrollment in pivotal trials, potentially expanding treatment options for this progressive retinal disease.
Conclusion
Laru-zova demonstrates a favorable safety profile and encouraging efficacy signals in XLRP patients, warranting further investigation in ongoing pivotal studies. This gene therapy approach holds promise for restoring photoreceptor function in this challenging genetic disorder.
References
- Beacon Therapeutics/ARVO 2025 -- Interim Data on Laru-zova Gene Therapy for XLRP
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.